RS-202

N/A

Report date: 2025/04/09 17:28:36

Base Information

Drug NameRS-202
Drug Alias NameRS-202RS202
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulatorsProgrammed cell death protein 1 modulators +[4] 
TargetsB-lymphocyte antigen CD19Programmed cell death protein 1Interleukin-15
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesRuichuang Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWyze Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A